Early diagnosis of rheumatoid arthritis: an introduction to the newly designed Iran Criteria for Rheumatoid Arthritis

Salehi, Iraj; Khazaeli, Shabnam; Khak, Mohammad
January 2013
Rheumatology International;Jan2013, Vol. 33 Issue 1, p45
Academic Journal
More than 14 years of clinical practice in rheumatology led the author to discover the prognostic role of anti-citrullinated protein antibody (ACPA) as well as the erosions found by MRI, in detecting the RA patients resulting in establishing a new set of criteria by revising the 1987 ACR classification-Iran Criteria for Rheumatoid Arthritis. Medical records of 243 patients at the outpatient Rheumatology Clinic of the author (private sector) were reviewed for the data on the criteria of the 1987 ACR, 2010 ACR/European League against Rheumatism (EULAR), and Iran Criteria for RA. In addition to modifying the 1987 ACR classification, Iran Criteria for RA adds some additional information to the ACR criteria (including ACPA and bony erosions detected by MRI), and any patient who satisfies 6 out of 12 points is considered as a definite RA patient. Sensitivity of the three classifications was calculated considering the clinical diagnosis by a single rheumatologist as the gold standard. A total of 63 male and 180 female patients with a mean follow-up duration of 28.24 ± 50.19 months were considered. Mean age at diagnosis and mean disease duration were 49.16 ± 15.38 years and 7.04 ± 6.87 months, respectively. The sensitivity for Iran Criteria for RA, 1987 ACR classification, and 2010 ACR/EULAR criteria were calculated as 98.4, 59.7, and 66.3%, respectively. Comparing Iran Criteria for RA with ACR and ACR/EULAR criteria, it was concluded that our newly introduced criteria is a more sensitive instrument in determining RA patients in the early stages of the disease.


Related Articles

  • Using Biologic Agents in Pediatric Rheumatologic Diseases. Unsal, Erbil // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Mar2010, Vol. 9 Issue 1, p41 

    Juvenile Idiopathic Arthritis (JIA) is an "umbrella" term which is used to cover Juvenile Rheumatoid Arthritis (JRA) and Juvenile Chronic Arthritis (JCA). Biologic agents are needed when others like NSAIDs (Non-steroidal antiinflammatory agents), DMARDs (Disease modifying antirheumatic drugs)...

  • How does the Short Form 36 Health Questionnaire (SF-36) in Rheumatoid Arthritis (RA) Relate to RA Outcome Measures and SF-36 Population Values? A Cross-Sectional Study. Birrell, F. N.; Hassell, A. B.; Jones, P. W.; Dawes, P. T. // Clinical Rheumatology;May2000, Vol. 19 Issue 3, p195 

    : The aim of the study was to show that the SF-36 is a practical tool for use on outpatients with RA, to examine the relationship between the SF-36 and indices of outcome in RA, and to compare the results with population norms and other disease states. Eighty-six consecutive RA patients...

  • MRI in rheumatoid arthritis: a useful tool for the clinician? McQueen, Fiona M. // Postgraduate Medical Journal;Jun2014, Vol. 90 Issue 1064, p332 

    Over the last two decades, MRI has emerged as an important clinical tool to assist in the diagnosis and management of rheumatic disease. In rheumatoid arthritis (RA), MRI has improved our understanding of the pathological basis of disease and has provided new information about imaging features...

  • Modulation of immune and inflammatory responses on experimental arthritis following intraarticular gene transfer of tumor necrosis factor receptor-immunoglobulin Fc. Zhou, Xiaobing; Gao, Kai; Shen, Lianzhong; Zhao, Aizhi; Wu, Xiaobing; Wang, Chao; Wang, Junzhi; Li, Bo // Rheumatology International;Sep2012, Vol. 32 Issue 9, p2605 

    In spite of popularity of TNF-α antagonist in the treatment of rheumatoid arthritis (RA), their modes of action are not fully understood. In the present study, we further explore the effects of gene transfer route of a TNF-α antagonist on arthritis. Recombinant adeno-associated virus 2...

  • National Meeting of the American College of Rheumatology. Badii, Maziar // Clinical & Investigative Medicine;Apr99, Vol. 22 Issue 2, p63 

    Provides information on the 62nd meeting of the American College of Rheumatology on November 1998 in San Diego, California. Approaches to the treatment of rheumatoid arthritis; Tumor necrosis factor alpha blockade; Leflunomide; Combination second-line therapy.

  • Rheumatoid arthritis patients should be referred more swiftly. Dobson, Roger // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/9/2009, Vol. 338 Issue 7703, p1097 

    The article reports on a consensus statement on the treatment of rheumatoid arthritis in Great Britain that was published in a 2009 issue of "Rheumatology". The authors of the statement suggested that patients with rheumatoid arthritis should be referred to a specialist rheumatology clinic as...

  • Report from the American College of Rheumatology Annual Scientific Meeting 2009. Ruderman, Eric // International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p137 

    Information about the American College of Rheumatology Annual Scientific Meeting held in Philadelphia, Pennsylvania on October 17 to 21, 2009 is presented. It states that the event highlights several proposed new therapies and additional information on the existing treatments rheumatoid...

  • Rheumatology. Bradlow, Anthony; David, Joel // BMJ: British Medical Journal (International Edition);3/11/95, Vol. 310 Issue 6980, p637 

    Outlines drug safety, screening policies and proactive approaches to chronic diseases which characterizes recent advances in rheumatology. Studies on non-steroidal anti-inflammatory agents; Usefulness in the reduction of severity of rheumatoid arthritis found in the trials of monoclonal...

  • Treatment of Rheumatoid Arthritis New Therapeutic Approaches with Biological Agents. Afeltra, A. // Current Drug Targets - Immune, Endocrine & Metabolic Disorders;May2001, Vol. 1 Issue 1, p45 

    Rheumatoid arthritis is a chronic polyarthritis leading to joint destruction and remarkable disability. Current therapies have various degrees of efficacy, but toxicity frequently limits their long-term use. Furthermore, treatment of refractory rheumatoid arthritis includes increasing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics